Eledon Pharmaceuticals (ELDN) Cash & Current Investments (2016 - 2017)
Historic Cash & Current Investments for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q3 2017 value amounting to $19.2 million.
- Eledon Pharmaceuticals' Cash & Current Investments rose 286.63% to $19.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $19.2 million, marking a year-over-year increase of 286.63%. This contributed to the annual value of $1.1 million for FY2016, which is 9529.2% down from last year.
- As of Q3 2017, Eledon Pharmaceuticals' Cash & Current Investments stood at $19.2 million, which was up 286.63% from $22.6 million recorded in Q2 2017.
- Eledon Pharmaceuticals' Cash & Current Investments' 5-year high stood at $105.5 million during Q3 2014, with a 5-year trough of $1.1 million in Q4 2016.
- In the last 5 years, Eledon Pharmaceuticals' Cash & Current Investments had a median value of $24.2 million in 2015 and averaged $38.3 million.
- In the last 5 years, Eledon Pharmaceuticals' Cash & Current Investments skyrocketed by 24856.74% in 2015 and then plummeted by 9529.2% in 2016.
- Over the past 5 years, Eledon Pharmaceuticals' Cash & Current Investments (Quarter) stood at $31.8 million in 2013, then soared by 231.48% to $105.3 million in 2014, then crashed by 77.18% to $24.0 million in 2015, then tumbled by 95.29% to $1.1 million in 2016, then surged by 1594.43% to $19.2 million in 2017.
- Its Cash & Current Investments was $19.2 million in Q3 2017, compared to $22.6 million in Q2 2017 and $24.4 million in Q1 2017.